Biotech company Invenra announced recently that it raised more than $2 million dollars from investors.

According to Vice President Mark Kubik, the funds will be used primarily for working capital and to continue to invest in technology and product development around Invenra’s next generation antibody and empowered antibody therapeutic discovery platform.

“The funds provide validation from the investment perspective,” Kubik said. “From a market and commercial validation perspective … these funds raised will be essential toward achieving that objective in the near future.

Invenra’s proprietary technology combines the cell-free expression of full-length antibodies with extreme miniaturization, according to its website.